-73%

est. 2Y upside i

HealthcareSeries A

Rank

#3381

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

Stylus Medicine, a Series A clinical-stage biotech, possesses a strong competitive moat with its novel in vivo gene editing platform, addressing significant challenges in CAR-T therapy.

Last updated: March 10, 2026

Bull (15%)+300%

Early, compelling preclinical data translates into rapid IND approval and promising Phase 1/2 clinical trial results for their lead in vivo CAR-T program in oncology, demonstrating superior safety and efficacy compared to existing ex vivo therapies. This attracts a major pharmaceutical partnership or acquisition at a valuation of $1.4B to $1.75B, reflecting the platform's potential.

Base (40%)+20%

Stylus Medicine successfully advances its lead program into early clinical trials, achieving initial safety milestones and demonstrating proof-of-concept for its in vivo gene editing platform. Progress is steady but slower than in the bull case, with ongoing capital raises at modest step-ups, leading to a valuation of $400M-$500M.

Bear (45%)-80%

Preclinical or early clinical development encounters unexpected safety concerns or efficacy limitations, or a major incumbent's competing in vivo therapy achieves significant clinical breakthroughs. This leads to a down round or a challenging funding environment, resulting in a valuation of $70M-$100M, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $85M in liquidation preferences, representing 24% of the estimated current $350M valuation, meaning common stock could be significantly impacted in a down round or exit at or below current valuation.

Dilution Risk

high

As a clinical-stage biotech, Stylus Medicine will require substantial additional funding rounds to advance its pipeline, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Stylus Medicine's equity at this early stage.

Questions to Ask at the Interview

Strategic questions based on Stylusmedicine's data — designed to show you've done your homework.

  • 1

    “Given the rapid M&A activity in the in vivo CAR-T space by major pharmaceutical companies like AbbVie and AstraZeneca, how does Stylus Medicine view its strategic positioning for partnerships or potential acquisition versus building out an independent commercial entity?”

  • 2

    “Stylus Medicine's platform aims to overcome limitations of ex vivo therapies using its recombinase-based gene insertion. What are the key preclinical data points you've generated that give you the most confidence in the safety and durability of your approach in a human clinical setting?”

  • 3

    “Considering the high capital intensity of clinical-stage biotech and the Series A funding, what is the anticipated timeline and strategy for future funding rounds, and how is the company managing potential dilution for early employees?”

Community

Valuation Sentiment

Our model estimates -73% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.